Perceptive Informatics Appoints Leading Imaging Expert Dr. Kenneth G. Faulkner to Vice President of Medical Imaging
BOSTON, July 28 /PRNewswire-FirstCall/ -- Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation , a leading global biopharmaceutical services organization, announced today that it has appointed Kenneth G. Faulkner, Ph.D., to the position of Vice President of Medical Imaging. Dr. Faulkner, who has 22 years of experience in the application of specialized medical imaging techniques in support of biopharmaceutical product development, will oversee medical imaging worldwide.
"Biopharmaceutical companies are increasingly using our novel medical imaging analyses as biomarkers or surrogate endpoints to assess safety and efficacy. Dr. Faulkner's in-depth experience will further strengthen Perceptive Informatics' medical imaging capabilities to help clients accelerate decisions about the development of new treatments," said Todd A. Joron, Corporate Vice President and General Manager of Perceptive Informatics at PAREXEL International.
Dr. Faulkner commented, "Perceptive Informatics is a clear leader in the field of medical imaging in support of clinical research, especially through the combination of its in-depth therapeutic expertise and advanced imaging technologies. I am excited to work with this high caliber global team and contribute my experience to help clients in the design and execution of their clinical studies across a broad range of therapeutic areas."
Prior to joining PAREXEL, Dr. Faulkner was Vice President of Scientific Services at Synarc, a provider of centralized imaging, molecular markers, and clinical research facilities, which he helped to found in 1998. Previously, he was Chief Scientist and Director of Marketing and Product Development for the Lunar Densitometry business unit of GE Healthcare that is dedicated to bone health. Dr. Faulkner received his Ph.D. in Biomedical Engineering from the University of California, Berkeley and San Francisco. Dr. Faulkner holds three patents related to the use of medical imaging for the assessment of osteoporosis, and has published over 70 scientific articles in the areas of osteoporosis diagnosis and treatment. He has served on the Boards of Directors of the International Society of Clinical Densitometry and Oregon Board of Radiologic Technology, and has participated as an advisor to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH).
The Perceptive Informatics Medical Imaging Division provides specialized services for clinical study sponsors who increasingly rely on medical imaging as a surrogate endpoint in assessing the efficacy and safety of new products. Perceptive Informatics radiology experts provide a range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology imaging.
About Perceptive Informatics, a PAREXEL Company
PAREXEL's Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive's portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(R) solution is Perceptive's market-leading CTMS product with 26,000 users worldwide, and Perceptive's INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit http://www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL and IMPACT are registered trademarks of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
International Corporation, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or
Rebecca Passo of SHIFT Communications for PAREXEL International
Corporation, +1-617-681-1217, rpasso@shiftcomm.com
Web site: http://www.parexel.com/
http://www.perceptive.com/